Jorge R Ledesma1, Jianing Ma1, Peng Zheng1,2, Jennifer M Ross3,4, Theo Vos1,2, Hmwe H Kyu5,6. 1. Institute for Health Metrics and Evaluation, University of Washington, 3980 15th Ave. NE, Seattle, WA, 98195, USA. 2. Department of Health Metrics Sciences, University of Washington, 3980 15th Ave. NE, Seattle, WA, 98195, USA. 3. Department of Global Health, University of Washington, 325 9th Avenue, Box 359931, Seattle, WA, 98104, USA. 4. Department of Medicine, University of Washington, 1959 NE Pacific Street, Box 356420, Seattle, WA, 98195, USA. 5. Institute for Health Metrics and Evaluation, University of Washington, 3980 15th Ave. NE, Seattle, WA, 98195, USA. hmwekyu@uw.edu. 6. Department of Health Metrics Sciences, University of Washington, 3980 15th Ave. NE, Seattle, WA, 98195, USA. hmwekyu@uw.edu.
Abstract
BACKGROUND: Identifying and treating individuals with high risk of progression from latent tuberculosis infection to active tuberculosis (TB) disease is critical for eliminating the disease. We aimed to conduct a systematic review and meta-regression analysis to quantify the dose-response relationship between interferon-gamma release assay (IGRA) levels and the risk of progression to active TB. METHODS: We searched PubMed and Embase from 1 January 2001 to 10 May 2020 for longitudinal studies that reported the risk of progression from latent to active TB as a function of baseline IGRA values. We used a novel Bayesian meta-regression method to pool effect sizes from included studies and generate a continuous dose-response risk curve. Our modeling framework enabled us to incorporate random effects across studies, and include data with different IGRA ranges across studies. The quality of included studies were assessed using the Newcastle-Ottawa scale (NOS). RESULTS: We included 34 studies representing 581,956 person-years of follow-up with a total of 788 incident cases of TB in the meta-regression analysis. Higher levels of interferon-gamma were associated with increased risk of progression to active tuberculosis. In the dose-response curve, the risk increased sharply between interferon-gamma levels 0 and 5 IU/ml, after which the risk continued to increase moderately but at a slower pace until reaching about 15 IU/ml where the risk levels off. Compared to 0 IU/ml, the relative risk of progression to active TB among those with interferon-gamma levels of 0.35, 1, 5, 10, 15, and 20 IU/ml were: 1.64 (1.28-2.08), 2.90 (2.02-3.88), 11.38 (6.64-16.38), 19.00 (13.08-26.90), 21.82 (14.65-32.57), and 22.31 (15.43-33.00), respectively. The dose-response relationship remains consistent when limiting the analysis to studies that scored highest in the NOS. CONCLUSION: The current practice of dichotomizing IGRA test results simplifies the TB infection disease continuum. Evaluating IGRA test results over a continuous scale could enable the identification of individuals at greatest risk of progression to active TB.
BACKGROUND: Identifying and treating individuals with high risk of progression from latent tuberculosis infection to active tuberculosis (TB) disease is critical for eliminating the disease. We aimed to conduct a systematic review and meta-regression analysis to quantify the dose-response relationship between interferon-gamma release assay (IGRA) levels and the risk of progression to active TB. METHODS: We searched PubMed and Embase from 1 January 2001 to 10 May 2020 for longitudinal studies that reported the risk of progression from latent to active TB as a function of baseline IGRA values. We used a novel Bayesian meta-regression method to pool effect sizes from included studies and generate a continuous dose-response risk curve. Our modeling framework enabled us to incorporate random effects across studies, and include data with different IGRA ranges across studies. The quality of included studies were assessed using the Newcastle-Ottawa scale (NOS). RESULTS: We included 34 studies representing 581,956 person-years of follow-up with a total of 788 incident cases of TB in the meta-regression analysis. Higher levels of interferon-gamma were associated with increased risk of progression to active tuberculosis. In the dose-response curve, the risk increased sharply between interferon-gamma levels 0 and 5 IU/ml, after which the risk continued to increase moderately but at a slower pace until reaching about 15 IU/ml where the risk levels off. Compared to 0 IU/ml, the relative risk of progression to active TB among those with interferon-gamma levels of 0.35, 1, 5, 10, 15, and 20 IU/ml were: 1.64 (1.28-2.08), 2.90 (2.02-3.88), 11.38 (6.64-16.38), 19.00 (13.08-26.90), 21.82 (14.65-32.57), and 22.31 (15.43-33.00), respectively. The dose-response relationship remains consistent when limiting the analysis to studies that scored highest in the NOS. CONCLUSION: The current practice of dichotomizing IGRA test results simplifies the TB infection disease continuum. Evaluating IGRA test results over a continuous scale could enable the identification of individuals at greatest risk of progression to active TB.
Entities:
Keywords:
Active tuberculosis; Dose-response meta-regression; IGRA; Latent tuberculosis
Authors: Neus Altet; José Dominguez; Maria-Luiza de Souza-Galvão; M Ángeles Jiménez-Fuentes; Célia Milà; Jordi Solsona; Antonio Soriano-Arandés; Irene Latorre; Elisa Lara; Adela Cantos; María Dolores Ferrer; Àngels Orcau; Juan Ruiz-Manzano; Joan Caylà Journal: Ann Am Thorac Soc Date: 2015-05
Authors: Jean-Pierre Zellweger; Giovanni Sotgiu; Michael Block; Simone Dore; Neus Altet; Rebecca Blunschi; Matthias Bogyi; Graham Bothamley; Christina Bothe; Luigi Codecasa; Patrizia Costa; Jose Dominguez; Raquel Duarte; Andreas Fløe; Isabelle Fresard; José-María García-García; Delia Goletti; Petra Halm; Doris Hellwig; Eveline Henninger; Helga Heykes-Uden; Liane Horn; Katarzyna Kruczak; Irene Latorre; Geneviève Pache; Heidrun Rath; Felix C Ringshausen; Asunción Seminario Ruiz; Ivan Solovic; Maria-Luiza de Souza-Galvão; Ursula Widmer; Peter Witte; Christoph Lange Journal: Am J Respir Crit Care Med Date: 2015-05-15 Impact factor: 21.405
Authors: Rishi K Gupta; Marc Lipman; Charlotte Jackson; Alice J Sitch; Jo Southern; Francis Drobniewski; Jonathan J Deeks; Chuen-Yan Tsou; Chris Griffiths; Jennifer Davidson; Colin Campbell; Oliver Stirrup; Mahdad Noursadeghi; Heinke Kunst; Pranab Haldar; Ajit Lalvani; Ibrahim Abubakar Journal: Am J Respir Crit Care Med Date: 2020-04-15 Impact factor: 21.405
Authors: Jerker Jonsson; Anna Westman; Judith Bruchfeld; Erik Sturegård; Hans Gaines; Thomas Schön Journal: PLoS One Date: 2017-11-02 Impact factor: 3.240